Open | $33.150 |
Close | $34.190 |
Volume / Avg. | 431.863K / 377.211K |
Day Range | 32.545 - 34.300 |
52 Wk Range | 21.990 - 39.090 |
Market Cap | $1.871B |
P/E Ratio | 1.651K |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 67 |
Short Interest | % |
Days to Cover | 9.85 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Supernus Pharmaceuticals (NASDAQ: SUPN) through any online brokerage.
Other companies in Supernus Pharmaceuticals’s space includes: Verona Pharma (NASDAQ:VRNA), CymaBay Therapeutics (NASDAQ:CBAY), Tarsus Pharmaceuticals (NASDAQ:TARS), Neumora Therapeutics (NASDAQ:NMRA) and ANI Pharmaceuticals (NASDAQ:ANIP).
The latest price target for Supernus Pharmaceuticals (NASDAQ: SUPN) was reported by Piper Sandler on Wednesday, February 28, 2024. The analyst firm set a price target for 41.00 expecting SUPN to rise to within 12 months (a possible 19.92% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Supernus Pharmaceuticals (NASDAQ: SUPN) is $34.19 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for Supernus Pharmaceuticals.
Supernus Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Supernus Pharmaceuticals.
Supernus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.